MicroRNAs and fibrosis

Vishal Patel; Lama Noureddine

doi:10.1097/MNH.0b013e328354e559

Back

Journal article

Peer reviewed

MicroRNAs and fibrosis

Vishal Patel and Lama Noureddine

Current opinion in nephrology and hypertension, Vol.21(4), pp.410-416

07/2012

DOI: 10.1097/MNH.0b013e328354e559

PMCID: PMC3399722

PMID: 22622653

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/3399722View

Open Access

Abstract

MicroRNAs (miRNAs) are short noncoding RNAs that inhibit gene expression in plants and animals. miRNAs have emerged as key players in virtually all aspects of mammalian biology. Aberrant miRNA expression is observed in numerous human diseases such as diabetes, hypercholesterolemia, cancer, and tissue fibrosis. Therefore, approaches to correct miRNA expression represent the novel therapeutic strategies for these diseases. miRNAs are essential for kidney development and homeostasis. Aberrant miRNA expression is observed in the mouse models of kidney fibrosis. Three TGF-β-regulated miRNA families, miR-21, miR-200, and miR-29 have been shown to modulate renal fibrosis. miR-21, through a feed-forward loop, amplifies TGF-β signaling and promotes fibrosis. Conversely, miR-200 and miR-29 reduce fibrosis by inhibiting epithelial-to-mesenchymal transition and preventing the deposition of extracellular matrix, respectively. Inhibition of miR-21 expression or augmenting miR-29 expression prevents kidney fibrosis in mice. Aberrant miRNA expression perturbs signaling pathways that lead to progression of kidney fibrosis. Thus, miRNAs represent novel biomarkers and therapeutic targets in the treatment of kidney fibrosis.

Genetic Markers

MicroRNAs - therapeutic use

Genetic Therapy

Kidney - pathology

Kidney Diseases - pathology

Humans

Gene Expression Regulation

MicroRNAs - metabolism

Kidney Diseases - genetics

Kidney - metabolism

Animals

Fibrosis

Kidney Diseases - therapy

Transforming Growth Factor beta - metabolism

Kidney Diseases - metabolism

Details

Title: Subtitle: MicroRNAs and fibrosis
Creators: Vishal Patel - Division of Nephrology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. Vishald.patel@utsouthwestern.edu
Lama Noureddine
Resource Type: Journal article
Publication Details: Current opinion in nephrology and hypertension, Vol.21(4), pp.410-416
DOI: 10.1097/MNH.0b013e328354e559
PMID: 22622653
PMCID: PMC3399722
NLM abbreviation: Curr Opin Nephrol Hypertens
ISSN: 1062-4821
eISSN: 1473-6543
Grant note: 5RC1DK086887-02 / NIDDK NIH HHS P30DK079328 / NIDDK NIH HHS RC1 DK086887 / NIDDK NIH HHS T32 DK007257 / NIDDK NIH HHS KO8 DK084311-01 / NIDDK NIH HHS T32DK007257 / NIDDK NIH HHS P30 DK079328 / NIDDK NIH HHS K08 DK084311 / NIDDK NIH HHS
Language: English
Date published: 07/2012
Academic Unit: Nephrology; Internal Medicine
Record Identifier: 9984094558502771

Metrics

18 Record Views

151 Times Cited - Web of Science